tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Abivax prices 10.2M ADSs at $64.00 in underwritten public offering
The FlyAbivax prices 10.2M ADSs at $64.00 in underwritten public offering
4d ago
ABVX
Abivax 10.16M ADS offering priced at $64.00
PremiumThe Fly
Abivax 10.16M ADS offering priced at $64.00
4d ago
ABVX
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
PremiumRatings
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
4d ago
ABVX
Abivax announces trading resumption of shares on Euronext Paris
PremiumThe Fly
Abivax announces trading resumption of shares on Euronext Paris
4d ago
ABVX
Abivax $400M Spot Secondary; price range $62.50-$65.00
PremiumThe Fly
Abivax $400M Spot Secondary; price range $62.50-$65.00
5d ago
ABVX
Abivax announces $400M ADS offering
PremiumThe FlyAbivax announces $400M ADS offering
5d ago
ABVX
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
Premium
The Fly
Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
5d ago
T
U
Abivax price target raised to $101 from $45 at LifeSci Capital
Premium
The Fly
Abivax price target raised to $101 from $45 at LifeSci Capital
5d ago
ABVX
Abivax upgraded to Overweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Abivax upgraded to Overweight from Equal Weight at Morgan Stanley
5d ago
ABVX
Abivax upgraded to Overweight at Morgan Stanley after obefazimod data
PremiumThe Fly
Abivax upgraded to Overweight at Morgan Stanley after obefazimod data
5d ago
ABVX
Abivax price target raised to $101 from $50 at Guggenheim
PremiumThe Fly
Abivax price target raised to $101 from $50 at Guggenheim
5d ago
ABVX
Abivax price target raised to $70 from $42 at Piper Sandler
PremiumThe Fly
Abivax price target raised to $70 from $42 at Piper Sandler
5d ago
ABVX
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
PremiumRatingsPromising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
5d ago
ABVX
Abivax price target raised to $95 from $33 at Citizens JMP
Premium
The Fly
Abivax price target raised to $95 from $33 at Citizens JMP
5d ago
ABVX
Abivax SA – American Depositary Shares trading resumes
Premium
The Fly
Abivax SA – American Depositary Shares trading resumes
6d ago
ABVX
Abivax says obefazimod met primary endpoint in ABTECT-1, ABTECT-2 trials
PremiumThe Fly
Abivax says obefazimod met primary endpoint in ABTECT-1, ABTECT-2 trials
6d ago
ABVX
Abivax SA – American Depositary Shares trading halted, news pending
PremiumThe Fly
Abivax SA – American Depositary Shares trading halted, news pending
6d ago
ABVX
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
19d ago
ABVX
PTGX
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
PremiumRatings
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact
22d ago
ABVX
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
PremiumRatingsPositive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment
24d ago
ABVX
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
Premium
Ratings
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease
1M ago
ABVX
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends
Premium
Ratings
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends
2M ago
ABVX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >